A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
Status:
Completed
Trial end date:
2020-02-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy and safety of KRN23 administered
subcutaneously once every 2 weeks in children with X-linked hypophosphatemic
rickets/osteomalacia(XLH)